Regulus Therapeutics Inc

NASDAQ RGLS

Data sourced from

and

Download Data

Regulus Therapeutics Inc Revenue Per Share for the year ending December 31, 2023: USD 0.00

Regulus Therapeutics Inc Revenue Per Share is USD 0.00 for the year ending December 31, 2023, a 0.00% change year over year. Revenue per share measures the amount of revenue generated by a company per outstanding share. It is calculated by dividing the revenue by the number of outstanding shares (weighted average). This ratio provides insights into the company's revenue generation on a per-share basis. A higher revenue per share indicates stronger revenue performance and potentially higher value per share for investors.

Regulus Therapeutics Inc Revenue Per Share for the year ending December 31, 2022 was USD 0.00, a -100.00% change year over year.
Regulus Therapeutics Inc Revenue Per Share for the year ending December 31, 2021 was USD 0.00, a -99.96% change year over year.
Regulus Therapeutics Inc Revenue Per Share for the year ending December 31, 2020 was USD 2.86, a -27.73% change year over year.
Regulus Therapeutics Inc Revenue Per Share for the year ending December 31, 2019 was USD 3.96, a 4,693.08% change year over year.

NASDAQ: RGLS

Regulus Therapeutics Inc

CEO	Mr. Joseph P. Hagan M.B.A.
IPO Date	Oct. 4, 2012
Location	United States
Headquarters	4224 Campus Point Court, San Diego, CA, United States, 92121
Employees	30
Sector	Healthcare
Industry	Biotechnology

Description

Regulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Key trends